Press releasePRNewswire
Carisma Therapeutics
CARM · NASDAQ
$0.0005+$0.0003 (+150.00%)TodayMarket closed ·
Prev close $0.0002
Latest news
- News
CARISMA Therapeutics Q3 EPS $1.07 Beats $(0.12) Estimate, Sales $45.250M Beat $3.771M Estimate
- NewsAvi Kapoor
Dow Surges 150 Points; US Consumer Sentiment Edges Lower
- NewsAvi Kapoor
Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
- NewsAvi Kapoor
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTY
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, BASE, CARM, ENZB on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders
- Press releaseBusiness Wire
CARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders
- Press releaseGlobe Newswire
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Rises Over 50 Points; US Inflation Rate Increases In May
- NewsAvi Kapoor
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
Carisma Therapeutics Provides Corporate Updates
- Press releaseBusiness Wire
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
- Press releasePRNewswire
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
- Press releasePRNewswire
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Press releasePRNewswire
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
- Press releasePRNewswire
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
- Press releasePRNewswire
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
- Press releasePRNewswire
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
- Press releasePRNewswire
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Press releasePRNewswire
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
- Press releasePRNewswire
Carisma Therapeutics Announces Changes to its Board of Directors
- Press releasePRNewswire
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
- Press releasePRNewswire
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.